Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Gynecologic Oncology|February 28, 1998
Evaluation of cisplatin and cyclosporin A in recurrent platinum-resistant ovarian cancer: a phase II study of the gynecologic oncology groupA Manetta, J A Blessing, J A Hurteau
Gynecologic Oncology|September 5, 2001
DNA methylation in ovarian cancer. II. Expression of DNA methyltransferases in ovarian cancer cell lines and normal ovarian epithelial cellsA Ahluwalia, J A Hurteau, R M Bigsby, et al.
Gynecologic Oncology|July 1, 1997
Complete hydatidiform mole coexisting with a twin live fetus: clinical courseJ A Hurteau, L M Roth, J M Schilder, et al.
Gynecologic Oncology|October 5, 2001
Cervical primitive neuroectodermal tumorA S Tsao, L M Roth, A Sandler, et al.
Gynecologic Oncology|February 18, 1999
Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: A Gynecologic Oncology Group studyH D Homesley, B N Bundy, J A Hurteau, et al.
Investigational New Drugs|April 9, 2001
A phase II trial of pyrazoloacridine (PZA) in squamous carcinoma of the cervix--a Gynecologic Oncology Group StudyS C Plaxe, J A Blessing, J A Lucci, et al.
American Journal of Obstetrics and Gynecology|December 18, 2001
Effect of carbon dioxide on human ovarian carcinoma cell growthV J Smidt, D M Singh, J A Hurteau, et al.
Gynecologic Oncology|September 10, 1999
Trisomy 21 associated with ovarian dysgerminomaJ D Smucker, L M Roth, G P Sutton, et al.
Gynecologic Oncology|June 28, 2001
Evaluation of recombinant human interleukin-12 in patients with recurrent or refractory ovarian cancer: a gynecologic oncology group studyJ A Hurteau, J A Blessing, S L DeCesare, et al.
American Journal of Obstetrics and Gynecology|March 1, 1994
Levels of soluble interleukin-2 receptor-alpha are elevated in serum and ascitic fluid from epithelial ovarian cancer patientsJ A Hurteau, H U Simon, C Kurman, et al.
Pageof 3